[1] Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, Özge A, Krymchantowski AV, Lebedeva ER, Ravishankar K, Yu S, Sacco S, Ashina S, Younis S, Steiner TJ, Lipton RB. Migraine:epidemiology and systems of care[J]. Lancet, 2021, 397:1485-1495.
[2] Ashina M. Migraine[J]. N Engl J Med, 2020, 383:1866-1876.
[3] GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016:a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet, 2017, 390:1211-1259.
[4] Homma S, Messé SR, Rundek T, Sun YP, Franke J, Davidson K, Sievert H, Sacco RL, Di Tullio MR. Patent foramen ovale[J]. Nat Rev Dis Primers, 2016, 2:15086.
[5] Koutroulou I, Tsivgoulis G, Tsalikakis D, Karacostas D, Grigoriadis N, Karapanayiotides T. Epidemiology of patent foramen ovale in general population and in stroke patients:a narrative review[J]. Front Neurol, 2020, 11:281.
[6] Zhang YS, Jiang SL, Zhu XY. Chinese expert guidelines for the prevention of patent foramen ovale-associated stroke[J]. Xin Zang Za Zhi, 2021, 33:1-10[.张玉顺, 蒋世良, 朱鲜阳. 卵圆孔未闭相关卒中预防中国专家指南[J]. 心脏杂志, 2021, 33:1-10.]
[7] Windecker S, Stortecky S, Meier B. Paradoxical embolism[J]. J Am Coll Cardiol, 2014, 64:403-415.
[8] Elgendy AY, Saver JL, Amin Z, Boudoulas KD, Carroll JD, Elgendy IY, Grunwald IQ, Gertz ZM, Hijazi ZM, Horlick EM, Kasner SE, Kent DM, Kumar P, Kavinsky CJ, Liebeskind DS, Lutsep H, Mojadidi MK, Messé SR, Mas JL, Mattle HP, Meier B, Mahmoud A, Mahmoud AN, Nietlispach F, Patel NK, Rhodes JF, Reisman M, Sommer RJ, Sievert H, Søndergaard L, Zaman MO, Thaler D, Tobis JM. Proposal for updated nomenclature and classification of potential causative mechanism in patent foramen ovale-associated stroke[J]. JAMA Neurol, 2020, 77:878-886.
[9] He D, Li Q, Xu G, Hu Z, Li X, Guo Y, Xu S, Wang W, Luo X. Clinical and imaging characteristics of PFO-related stroke with different amounts of right-to-left shunt[J]. Brain Behav, 2018, 8:e01122.
[10] Liu F, Kong Q, Zhang X, Li Y, Liang S, Han S, Li G. Comparative analysis of the diagnostic value of several methods for the diagnosis of patent foramen ovale[J]. Echocardiography, 2021, 38:790-797.
[11] Yang X, Wang H, Wei Y, Zhai N, Liu B, Li X. Diagnosis of patent foramen ovale:the combination of contrast transcranial doppler, contrast transthoracic echocardiography, and contrast transesophageal echocardiography[J]. Biomed Res Int, 2020:ID8701759.
[12] Pristipino C, Sievert H, D'Ascenzo F, Louis Mas J, Meier B, Scacciatella P, Hildick-Smith D, Gaita F, Toni D, Kyrle P, Thomson J, Derumeaux G, Onorato E, Sibbing D, Germonpré P, Berti S, Chessa M, Bedogni F, Dudek D, Hornung M, Zamorano J; Evidence Synthesis Team; Eapci Scientific Documents and Initiatives Committee; International Experts. European position paper on the management of patients with patent foramen ovale:general approach and left circulation thromboembolism[J]. Eur Heart J, 2019, 40:3182-3195.
[13] Katsanos AH, Psaltopoulou T, Sergentanis TN, Frogoudaki A, Vrettou AR, Ikonomidis I, Paraskevaidis I, Parissis J, Bogiatzi C, Zompola C, Ellul J, Triantafyllou N, Voumvourakis K, Kyritsis AP, Giannopoulos S, Alexandrov AW, Alexandrov AV, Tsivgoulis G. Transcranial doppler versus transthoracic echocardiography for the detection of patent foramen ovale in patients with cryptogenic cerebral ischemia:a systematic review and diagnostic test accuracy meta-analysis[J]. Ann Neurol, 2016, 79:625-635.
[14] Del Sette M, Angeli S, Leandri M, Ferriero G, Bruzzone GL, Finocchi C, Gandolfo C. Migraine with aura and right-to-left shunt on transcranial Doppler:a case-control study[J]. Cerebrovasc Dis, 1998, 8:327-330.
[15] Tariq N, Tepper SJ, Kriegler JS. Patent foramen ovale and migraine:closing the debate:a review[J]. Headache, 2016, 56:462-478.
[16] Kumar P, Kijima Y, West BH, Tobis JM. The connection between patent foramen ovale and migraine[J]. Neuroimaging Clin N Am, 2019, 29:261-270.
[17] Küper M, Rabe K, Holle D, Savidou I, Dommes P, Frings M, Diener HC, Katsarava Z. Prevalence of cardiac right left shunts in migraine:a population-based case-control study[J]. Neurol Sci, 2013, 34:205-208.
[18] Rundek T, Elkind MS, Di Tullio MR, Carrera E, Jin Z, Sacco RL, Homma S. Patent foramen ovale and migraine:a cross-sectional study from the Northern Manhattan Study (NOMAS)[J]. Circulation, 2008, 118:1419-1424.
[19] Alpert JS. Strange bedfellows:migraine headache and patent foramen ovale[J]. Am J Med, 2021, 134:1307-1308.
[20] Takizawa T, Ayata C, Chen SP. Therapeutic implications of cortical spreading depression models in migraine[J]. Prog Brain Res, 2020, 255:29-67.
[21] Nozari A, Dilekoz E, Sukhotinsky I, Stein T, Eikermann-Haerter K, Liu C, Wang Y, Frosch MP, Waeber C, Ayata C, Moskowitz MA. Microemboli may link spreading depression, migraine aura, and patent foramen ovale[J]. Ann Neurol, 2010, 67:221-229.
[22] Wilmshurst P, Nightingale S. Relationship between migraine and cardiac and pulmonary right-to-left shunts[J]. Clin Sci (Lond), 2001, 100:215-220.
[23] Wilmshurst P, Nightingale S. The role of cardiac and pulmonary pathology in migraine:a hypothesis[J]. Headache, 2006, 46:429-434.
[24] Steele JG, Nath PU, Burn J, Porteous ME. An association between migrainous aura and hereditary haemorrhagic telangiectasia[J]. Headache, 1993, 33:145-148.
[25] Spence JD, Wong DG, Melendez LJ, Nichol PM, Brown JD. Increased prevalence of mitral valve prolapse in patients with migraine[J]. Can Med Assoc J, 1984, 131:1457-1460.
[26] Bridges ND, Hellenbrand W, Latson L, Filiano J, Newburger JW, Lock JE. Transcatheter closure of patent foramen ovale after presumed paradoxical embolism[J]. Circulation, 1992, 86:1902-1908.
[27] Wilmshurst PT, Nightingale S, Walsh KP, Morrison WL. Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons[J]. Lancet, 2000, 356:1648-1651.
[28] Liu K, Wang BZ, Hao Y, Song S, Pan M. The correlation between migraine and patent foramen ovale[J]. Front Neurol, 2020, 11:543485.
[29] Qi Y, Zhang Y, Luo X, Cheng G, Du Y, Liu R, Xie H, Cheng Y, Guo Y, Luo G. Efficacy of patent foramen ovale closure for treating migraine:a prospective follow-up study[J]. J Investig Med, 2021, 69:7-12.
[30] Xing YQ, Guo YZ, Gao YS, Guo ZN, Niu PP, Yang Y. Effectiveness and safety of transcatheter patent foramen ovale closure for migraine (EASTFORM) trial[J]. Sci Rep, 2016, 6:39081.
[31] He YD, Yan XL, Qin C, Zhang P, Guo ZN, Yang Y. Transcatheter patent foramen ovale closure is effective in alleviating migraine in a 5-year follow-up[J]. Front Neurol, 2019, 10:1224.
[32] Meier B, Nietlispach F. Device closure of the patent foramen:the longer you look, the more you like it[J]. J Am Coll Cardiol, 2019, 73:288-290.
[33] Dowson A, Mullen MJ, Peatfield R, Muir K, Khan AA, Wells C, Lipscombe SL, Rees T, De Giovanni JV, Morrison WL, Hildick-Smith D, Elrington G, Hillis WS, Malik IS, Rickards A. Migraine Intervention With STARFlex Technology (MIST) trial:a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache[J]. Circulation, 2008, 117:1397-1404.
[34] Mattle HP, Evers S, Hildick-Smith D, Becker WJ, Baumgartner H, Chataway J, Gawel M, Göbel H, Heinze A, Horlick E, Malik I, Ray S, Zermansky A, Findling O, Windecker S, Meier B. Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial[J]. Eur Heart J, 2016, 37:2029-2036.
[35] Tobis JM, Charles A, Silberstein SD, Sorensen S, Maini B, Horwitz PA, Gurley JC. Percutaneous closure of patent foramen ovale in patients with migraine:the PREMIUM trial[J]. J Am Coll Cardiol, 2017, 70:2766-2774.
[36] Mas JL, Guillon B, Charles-Nelson A, Domigo V, Derex L, Massardier E, Arquizan C, Vuillier F, Timsit S, Béjot Y, Detante O, Sablot D, Guidoux C, Sibon I, Dequatre-Ponchelle N, Touzé E, Canaple S, Alamowitch S, Aubry P, Teiger E, Derumeaux G, Chatellier G; CLOSE investigators. Patent foramen ovale closure in stroke patients with migraine in the CLOSE trial:the CLOSE-MIG study[J]. Eur J Neurol, 2021, 28:2700-2707.
[37] Carroll JD. Migraine Intervention With STARFlex technology trial:a controversial trial of migraine and patent foramen ovale closure[J]. Circulation, 2008, 117:1358-1360.
[38] Zhang QQ, Lu JJ, Yan MY, Hu XW, Qin YR, Wang DP, Jiang JH, Fang Q, Zhao HR. The efficacy of percutaneous patent foramen ovale closure on migraine:a meta-analysis of randomized controlled trials and observational studies[J]. Biomed Res Int, 2021:ID6643266.
[39] Mojadidi MK, Kumar P, Mahmoud AN, Elgendy IY, Shapiro H, West B, Charles AC, Mattle HP, Sorensen S, Meier B, Silberstein SD, Tobis JM. Pooled analysis of PFO occluder device trials in patients with PFO and migraine[J]. J Am Coll Cardiol, 2021, 77:667-676.
[40] Zhao E, Xie H, Zhang Y. A nomogram for the prediction of cessation of migraine among patients with patent foramen ovale after percutaneous closure[J]. Front Neurol, 2020, 11:593074.
[41] Ben-Assa E, Rengifo-Moreno P, Al-Bawardy R, Kolte D, Cigarroa R, Cruz-Gonzalez I, Sakhuja R, Elmariah S, Pomerantsev E, Vaina LM, Ning M, Buonanno FS, Hung JW, Inglessis I, Palacios IF. Effect of residual interatrial shunt on migraine burden after transcatheter closure of patent foramen ovale[J]. JACC Cardiovasc Interv, 2020, 13:293-302.
[42] Shi YJ, Lv J, Han XT, Luo GG. Migraine and percutaneous patent foramen ovale closure:a systematic review and meta-analysis[J]. BMC Cardiovasc Disord, 2017, 17:203.
[43] Guo Y, Shi Y, Zhu D, Liu R, Qi Y, Luo G. Clopidogrel can be an effective complementary prophylactic for drug-refractory migraine with patent foramen ovale[J]. J Investig Med, 2020, 68:1250-1255.
[44] Sommer RJ, Nazif T, Privitera L, Robbins BT. Retrospective review of thienopyridine therapy in migraineurs with patent foramen ovale[J]. Neurology, 2018, 91:1002-1009.
[45] Reisman AM, Robbins BT, Chou DE, Yugrakh MS, Gross GJ, Privitera L, Nazif T, Sommer RJ. Ticagrelor for refractory migraine/patent foramen ovale (TRACTOR):an open-label pilot study[J]. Neurology, 2018, 91:1010-1017.
[46] Przemys?aw W, Spisak-Borowska K, Bochenek T, Konarska-Kuszewska E, Machowski J, Trusz-Gluza M, Bajor G, Mizia-Stec K, Giblett JP, Calvert PA. Impact of percutaneous patent foramen ovale closure on migraine headaches in patients with history of ischemic neurological events[J]. Postepy Kardiol Interwencyjnej, 2020, 16:315-320.
[47] Pristipino C, Germonpré P, Toni D, Sievert H, Meier B, D'Ascenzo F, Berti S, Onorato EM, Bedogni F, Mas JL, Scacciatella P, Hildick-Smith D, Gaita F, Kyrle PA, Thomson J, Derumeaux G, Sibbing D, Chessa M, Hornung M, Zamorano J, Dudek D, D'Ascenzo F, Omedè P, Ballocca F, Barbero U, Giordana F, Gili S, Iannaccone M, Akagi T, Anzola G, Carroll J, Dalvi B, Angelis C, Junbo G, Kasner SE, Michel-Behnke I, Musumeci G, Søndergaard L, Tarantini G, Biondi-Zoccai GGL, Capodanno D, Valgimigli M, Byrne R, Kunadian V; EVIDENCE SYNTHESIS TEAM; INTERNATIONAL EXPERTS; joint task force of European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Stroke Organisation (ESO), European Heart Rhythm Association (EHRA), European Association for Cardiovascular Imaging (EACVI), European Paediatric and Congenital Cardiology (AEPC), ESC Working Group on Adult Congenital Heart Disease, ESC Working Group on Thrombosis, European Haematological Society (EHA), European Underwater and Baromedical Society (EUBS); EAPCI SCIENTIFIC DOCUMENTS AND INITIATIVES COMMITTEE. European position paper on the management of patients with patent foramen ovale:part Ⅱ-decompression sickness, migraine, arterial deoxygenation syndromes and select high-risk clinical conditions[J]. Eur Heart J, 2021, 42:1545-1553.